Cargando…

3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15

Developing a technology that enables oral vaccines to work efficiently remains a considerable effort since a number of difficulties must be addressed. The key objective being to ensure the safe passage through the harsh conditions within the gastrointestinal tract, promoting delivery that induces en...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, Martin K., Kardjilov, Nikolay, Oliveira, Cristiano L. P., Watts, Benjamin, Villanova, Julie, Botosso, Viviane Fongaro, Sant’Anna, Osvaldo A., Fantini, Marcia C. A., Bordallo, Heloisa N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465313/
https://www.ncbi.nlm.nih.gov/pubmed/30988384
http://dx.doi.org/10.1038/s41598-019-42645-5
_version_ 1783410917809061888
author Rasmussen, Martin K.
Kardjilov, Nikolay
Oliveira, Cristiano L. P.
Watts, Benjamin
Villanova, Julie
Botosso, Viviane Fongaro
Sant’Anna, Osvaldo A.
Fantini, Marcia C. A.
Bordallo, Heloisa N.
author_facet Rasmussen, Martin K.
Kardjilov, Nikolay
Oliveira, Cristiano L. P.
Watts, Benjamin
Villanova, Julie
Botosso, Viviane Fongaro
Sant’Anna, Osvaldo A.
Fantini, Marcia C. A.
Bordallo, Heloisa N.
author_sort Rasmussen, Martin K.
collection PubMed
description Developing a technology that enables oral vaccines to work efficiently remains a considerable effort since a number of difficulties must be addressed. The key objective being to ensure the safe passage through the harsh conditions within the gastrointestinal tract, promoting delivery that induces enhanced immune response. In the particular case of hepatitis B, the oral formulation in the nanostructured silica SBA-15 is a viable approach. As a result of its porous structure, low toxicity and structural stability, SBA-15 is capable to protect and release the hepatitis B surface antigen (HBsAg), used in the vaccination scheme, at the desired destination. Furthermore, when compared to the currently used injection based delivery method, better or similar antibody response has been observed. However, information about the organisation of the antigen protein remains unknown. For instance, HBsAg is too large to enter the 10 nm ordered mesopores of SBA-15 and has a tendency to agglomerate when protected by the delivery system. Here we report on the pH dependence of HBsAg aggregation in saline solution investigated using small angle X-rays scattering that resulted in an optimisation of the encapsulation conditions. Additionally, X-ray microscopy combined with neutron and X-ray tomography provided full 3D information of the HBsAg clustering (i.e. agglomeration) inside the SBA-15 macropores. This method enables the visualisation of the organisation of the antigen in the interior of the delivery system, where agglomerated HBsAg coexists with its immunological effective uniformly distributed counterpart. This new approach, to be taken into account while preparing the formulation, can greatly help in the understanding of clinical studies and advance new formulations.
format Online
Article
Text
id pubmed-6465313
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-64653132019-04-18 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15 Rasmussen, Martin K. Kardjilov, Nikolay Oliveira, Cristiano L. P. Watts, Benjamin Villanova, Julie Botosso, Viviane Fongaro Sant’Anna, Osvaldo A. Fantini, Marcia C. A. Bordallo, Heloisa N. Sci Rep Article Developing a technology that enables oral vaccines to work efficiently remains a considerable effort since a number of difficulties must be addressed. The key objective being to ensure the safe passage through the harsh conditions within the gastrointestinal tract, promoting delivery that induces enhanced immune response. In the particular case of hepatitis B, the oral formulation in the nanostructured silica SBA-15 is a viable approach. As a result of its porous structure, low toxicity and structural stability, SBA-15 is capable to protect and release the hepatitis B surface antigen (HBsAg), used in the vaccination scheme, at the desired destination. Furthermore, when compared to the currently used injection based delivery method, better or similar antibody response has been observed. However, information about the organisation of the antigen protein remains unknown. For instance, HBsAg is too large to enter the 10 nm ordered mesopores of SBA-15 and has a tendency to agglomerate when protected by the delivery system. Here we report on the pH dependence of HBsAg aggregation in saline solution investigated using small angle X-rays scattering that resulted in an optimisation of the encapsulation conditions. Additionally, X-ray microscopy combined with neutron and X-ray tomography provided full 3D information of the HBsAg clustering (i.e. agglomeration) inside the SBA-15 macropores. This method enables the visualisation of the organisation of the antigen in the interior of the delivery system, where agglomerated HBsAg coexists with its immunological effective uniformly distributed counterpart. This new approach, to be taken into account while preparing the formulation, can greatly help in the understanding of clinical studies and advance new formulations. Nature Publishing Group UK 2019-04-15 /pmc/articles/PMC6465313/ /pubmed/30988384 http://dx.doi.org/10.1038/s41598-019-42645-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Rasmussen, Martin K.
Kardjilov, Nikolay
Oliveira, Cristiano L. P.
Watts, Benjamin
Villanova, Julie
Botosso, Viviane Fongaro
Sant’Anna, Osvaldo A.
Fantini, Marcia C. A.
Bordallo, Heloisa N.
3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15
title 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15
title_full 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15
title_fullStr 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15
title_full_unstemmed 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15
title_short 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15
title_sort 3d visualisation of hepatitis b vaccine in the oral delivery vehicle sba-15
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465313/
https://www.ncbi.nlm.nih.gov/pubmed/30988384
http://dx.doi.org/10.1038/s41598-019-42645-5
work_keys_str_mv AT rasmussenmartink 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT kardjilovnikolay 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT oliveiracristianolp 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT wattsbenjamin 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT villanovajulie 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT botossovivianefongaro 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT santannaosvaldoa 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT fantinimarciaca 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15
AT bordalloheloisan 3dvisualisationofhepatitisbvaccineintheoraldeliveryvehiclesba15